Residency · Residency · Otolaryngology

Obstructive Sleep Apnea in Adults: Evaluation and Non-Surgical Management

Introduction

Obstructive sleep apnea (OSA) is characterized by repetitive episodes of partial or complete upper airway collapse during sleep, resulting in intermittent hypoxemia and sleep fragmentation. OSA affects approximately 15-30% of males and 10-15% of females in the adult population. Untreated OSA is associated with significant cardiovascular morbidity, neurocognitive impairment, motor vehicle accidents, and increased mortality.

Pathophysiology

Upper Airway Collapse

The pharynx is a collapsible muscular tube with no rigid skeletal support. Balance between negative inspiratory pressure and dilator muscle activity determines patency. During sleep, pharyngeal muscle tone decreases, allowing collapse at susceptible sites. Critical closing pressure (Pcrit): The pharyngeal pressure at which collapse occurs; elevated in OSA patients. Collapse occurs most commonly at the retropalatal and retrolingual levels.

Contributing Factors

Anatomic factors: Obesity (fat deposition in the parapharyngeal spaces), retrognathia, macroglossia, tonsillar hypertrophy, elongated soft palate, deviated nasal septum. Neuromuscular factors: Decreased genioglossus activity during sleep, impaired protective reflexes. Ventilatory control instability: High loop gain (exaggerated ventilatory response) contributes to cycling apneas. Low arousal threshold: Premature awakening prevents stabilization of upper airway tone.

Clinical Presentation

Symptoms

Snoring: Present in nearly all patients; often the primary complaint of the bed partner. Witnessed apneas: Bed partner observes cessation of breathing followed by gasping. Excessive daytime sleepiness: Assessed by the Epworth Sleepiness Scale (ESS); score >10 suggests excessive sleepiness. Nonrestorative sleep, morning headaches, nocturia. Impaired concentration, memory deficits, mood disturbance. Decreased libido and erectile dysfunction.

Physical Examination

Body mass index (BMI); neck circumference >17 inches (males) or >16 inches (females) increases risk. Modified Mallampati score: Class III-IV associated with increased OSA severity. Friedman tongue position: Evaluates tongue base relative to palate. Tonsillar size (Brodsky grading: 0-4). Nasal examination: Septal deviation, turbinate hypertrophy, nasal valve collapse. Retrognathia/micrognathia: Assess mandibular position. Drug-induced sleep endoscopy (DISE): Evaluates dynamic airway collapse under sedation to identify obstruction sites.

Diagnostic Testing

Polysomnography (PSG)

In-laboratory PSG is the gold standard for OSA diagnosis. Records EEG, EOG, EMG, airflow, respiratory effort, oxygen saturation, body position, ECG. Apnea: Cessation of airflow for at least 10 seconds. Hypopnea: Reduction in airflow by at least 30% for 10 seconds with either 3% desaturation or arousal. Apnea-Hypopnea Index (AHI): Number of apneas and hypopneas per hour of sleep.

Home Sleep Apnea Testing (HSAT)

Portable monitoring for patients with high pretest probability of moderate-to-severe OSA. Records airflow, respiratory effort, and oximetry (limited channels compared to PSG). May underestimate severity due to lack of EEG (total recording time used as denominator). Not appropriate for patients with significant cardiopulmonary disease, suspected central apnea, or other sleep disorders.

Non-Surgical Management

Continuous Positive Airway Pressure (CPAP)

First-line therapy for moderate-to-severe OSA. Pneumatic splint that maintains upper airway patency throughout the respiratory cycle. Titrated during PSG or via auto-titrating (APAP) device. Optimal pressure typically ranges from 5-20 cm H2O. Efficacy is directly proportional to adherence; defined as use >4 hours per night on >70% of nights. Reduces AHI, improves daytime sleepiness, reduces blood pressure, and decreases cardiovascular risk.

CPAP Adherence Optimization

Proper mask fitting is essential; nasal, nasal pillow, and oronasal interfaces available. Heated humidification reduces nasal dryness and congestion. Pressure ramp feature allows gradual pressure increase at sleep onset. Expiratory pressure relief (EPR/C-Flex) improves comfort. Behavioral interventions and motivational counseling improve long-term compliance. Treat nasal obstruction to improve CPAP tolerance.

Oral Appliances

Mandibular advancement devices (MADs): Custom-fitted devices that protrude the mandible forward, enlarging the retrolingual airway. Indicated for mild-to-moderate OSA or for patients intolerant of CPAP. Less effective than CPAP in reducing AHI but may have better adherence. Custom devices fabricated by a dentist trained in sleep medicine are preferred over over-the-counter devices. Side effects: Temporomandibular joint discomfort, dental changes, excessive salivation.

Positional Therapy

Supine-predominant OSA: AHI at least twice as high in supine vs. non-supine position. Positional devices (bumper belts, vibrotactile devices) discourage supine sleep. Adjunctive therapy; rarely sufficient as monotherapy for moderate-to-severe OSA.

Weight Management

Obesity is the strongest modifiable risk factor for OSA. 10% weight loss can reduce AHI by approximately 26%. Bariatric surgery should be considered for morbidly obese patients (BMI >40). Weight loss improves but rarely cures moderate-to-severe OSA.

Pharmacotherapy

No FDA-approved medications specifically for OSA. Acetazolamide: May reduce AHI in patients with high loop gain. Atomoxetine-oxybutynin combination: Emerging evidence for reducing AHI by enhancing upper airway muscle tone. Treat contributing conditions: Hypothyroidism, nasal congestion (topical steroids).

Comorbidities and Consequences

Cardiovascular: Hypertension (resistant hypertension strongly associated), atrial fibrillation, heart failure, stroke, coronary artery disease. Metabolic: Insulin resistance, type 2 diabetes, metabolic syndrome. Neurocognitive: Impaired attention, memory deficits, depression. Perioperative risk: Increased risk of airway complications; screen preoperatively with STOP-BANG questionnaire.

Key Clinical Pearls

CPAP remains the first-line treatment for moderate-to-severe OSA; adherence is the primary challenge. Drug-induced sleep endoscopy (DISE) helps identify the specific site(s) of obstruction and guides surgical planning when non-surgical therapy fails. A neck circumference >17 inches and modified Mallampati class III-IV are strong predictors of OSA. Home sleep apnea testing may underestimate OSA severity and is not appropriate for patients with significant comorbidities. Weight loss is the most impactful lifestyle modification but rarely eliminates moderate-to-severe OSA completely.

References

1. Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263-276.
2. Patil SP, Ayappa IA, Caples SM, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: an AASM systematic review. J Clin Sleep Med. 2019;15(2):301-334.
3. Ramar K, Dort LC, Katz SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy. J Clin Sleep Med. 2015;11(7):773-827.
4. Eckert DJ, White DP, Jordan AS, et al. Defining phenotypic causes of obstructive sleep apnea. Am J Respir Crit Care Med. 2013;188(8):996-1004.

Read this lecture as Markdown